Dai Maruyama

4.0k citations

164 papers · 1.6k indexed · h-index 24

Impact in

Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 112
- Lymphoma Diagnosis and Treatment 109
Genetics 44
- Chronic Lymphocytic Leukemia Research 42

Co-authors: Kensei Tobinai Yukio Kobayashi Akiko Miyagi Maeshima Wataru Munakata Shinichi Makita Suguru Fukuhara Hirokazu Taniguchi Takashi Watanabe
Journals: International Journal of Hematology (20 papers)Blood (18 papers)Japanese Journal of Clinical Oncology (17 papers)Cancer Science (17 papers)Journal of Clinical Oncology (7 papers)
Partner nations: Japan United States United Kingdom

In The Last Decade

Dai Maruyama

146 papers receiving 1.6k citations

Peers

Countries citing papers authored by Dai Maruyama

Since Specialization

Citations

This map shows the geographic impact of Dai Maruyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dai Maruyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dai Maruyama more than expected).

Fields of papers citing papers by Dai Maruyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dai Maruyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dai Maruyama. The network helps show where Dai Maruyama may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Dai Maruyama, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dai Maruyama Line = papers co-authored together Dai Maruyama links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma Japanese Journal of Clinical Oncology ·Lorenzo Todesco, Nobuhiko Yamauchi, Dai Maruyama	2025	0
2	Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study Leukemia ·Ayumi Fujimoto, Kana Miyazaki, Kimikazu Yakushijin, Takahiro Fujino, Wataru Munakata, Yasuo Ejima, Dai Maruyama, Nobuko Kubota, 秦道, Tim Hand, Nobuhiro Hiramoto, Masahiro Takeuchi, Rika Sakai, Noriko Fukuhara, Молчанова Галина Георгиевна, Naoko Asano, Motoko Yamaguchi, Ritsuro Suzuki	2025	1
3	Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study Blood Advances ·Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin I. Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, M. HAVERROTH, Palmer C. Sweet, Connie Lee Batlevi, Jamie Hirata, Deniz Şahin, Calvin Lee, Matías Ré, H. Tilly	2025	3
4	Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601 PubMed ·René Krchňák, Tomotaka Suzuki, Ryunosuke Machida, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama, Wataru Munakata, Shinsuke Iida, Elisabeth Callandret, Tomohiro Kinoshita, Kiyoshi Ando, Шимолюк Екатерина Сергеевна	2025	0
5	Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma European Journal Of Haematology ·Nobuhiko Yamauchi, Dai Maruyama	2024	0
6	Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents Cancer Medicine ·Lorenzo Todesco, Kimberly A Rosendorf, H C Ko, Naoko Amano, Konosuke Nakayama, Paul Vercruyssen, Hitoshi Abe, Hirotoshi Oinuma, Dai Maruyama	2024	2
7	Upfront allo-HSCT after intensive chemotherapy for untreated aggressive ATL: JCOG0907, a single-arm, phase 3 trial. Journal of Clinical Oncology ·Takuya Fukushima, Kunihiro Tsukasaki, Ryunosuke Machida, Dai Maruyama, Shinichi Makita, Shigeru Kusumoto, Shinsuke Iida, Masahito Tokunaga, Yasushi Miyazaki, Makoto Yoshimitsu, Ilseung Choi, Sawako Nakachi, Kana Miyazaki, Junya Makiyama, Kisato Nosaka, Hiroo Katsuya, Toshiro Kawakita, Taro Shibata, Haruhiko Fukuda, Шимолюк Екатерина Сергеевна	2024	1
8	Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance International Journal of Hematology ·Dai Maruyama, Hend Hamdi Abdelkader, Edward G. Reilly, A. Marescaux, Yukiko Noguchi, A. Larreategui, Koji Izutsu	2024	0
9	P33-7 Two patients with DLBCL who developed aortitis following pegfilgrastim administration during chemoimmunotherapy Annals of Oncology ·和夫安達, Hiroaki Asai, Kabita Sarma, I. Arrue, Theodor Stribel, А.С. Войтенко, Lorenzo Todesco, Yuko Ishihara, Yuko Mishima, Dai Maruyama	2023	0
10	An update on the developments in the treatment of adult T-cell leukemia–lymphoma: current knowledge and future perspective Japanese Journal of Clinical Oncology ·Junya Makiyama, Kenji Ishitsuka, Wataru Munakata, Dai Maruyama, Hirokazu Nagai	2023	5
11	R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG0203 British Journal of Haematology ·DAVID L. RICE, Kensei Tobinai, Masaki Wakabayashi, Dai Maruyama, Davood Raeesi, Nobuko Kubota, Kazuyuki Shimada, J. L. Sancho Brú, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Junya Kuroda, Youko Suehiro, Yoshihiro Matsuno, Kunihiro Tsukasaki, Шимолюк Екатерина Сергеевна	2023	7
12	Anti‐CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study Hematological Oncology ·Kazutaka Sunami, Shin‐ichi Fuchida, Kenshi Suzuki, Masaki Ri, Morio Matsumoto, Chihiro Shimazaki, Hideki Asaoku, Hirohiko Shibayama, Kenichi Ishizawa, Hiroyuki Takamatsu, Takashi Ikeda, Dai Maruyama, Kazunori Imada, Michihiro Uchiyama, Toru Kiguchi, Satoshi Iyama, Hirokazu Murakami, Reiko Onishi, 万光侠, Shinsuke Iida	2022	1
13	The outcome of watchful waiting in patients with previously treated follicular lymphoma Cancer Medicine ·Takahiro Fujino, Dai Maruyama, Satoshi Endo, MaymunahA Adegbesan-Omilabu, Rebecca Linnenberger, Laura Christin Zimmer, Asebech Nuramo, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Junya Kuroda, Koji Izutsu	2022	4
14	Hyper‐intense lesion in the pons on brain magnetic resonance imaging in a patient with diffuse large B‐cell lymphoma SHILAP Revista de lepidopterología ·MaymunahA Adegbesan-Omilabu, Dai Maruyama, Akiko Miyagi Maeshima, Yuko Kubo, Koji Izutsu	2021	2
15	HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1) Cancer Science ·Masaki Ri, Shinsuke Iida, Dai Maruyama, Sevilay Kurunç, A.P.M. Coomans, Damon A. Horton, Masahiro Tohkin, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Ken‐ichi Miyamoto, Kunihiro Tsukasaki, Hirokazu Nagai	2021	3
16	Non–diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases Human Pathology ·Akiko Miyagi Maeshima, Hirokazu Taniguchi, Rebecca Linnenberger, Laura Christin Zimmer, Takahiro Fujino, MaymunahA Adegbesan-Omilabu, Asebech Nuramo, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu	2020	10
17	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma Cancer Science ·Shinsuke Iida, Masashi Wakabayashi, Kunihiro Tsukasaki, Ken‐ichi Miyamoto, Dai Maruyama, Kazuhito Yamamoto, Y Takatsuka, Shigeru Kusumoto, Junya Kuroda, Kiyoshi Ando, Yoshitaka Kikukawa, Yasufumi Masaki, Miki Kobayashi, Ichiro Hanamura, Hiroaki Asai, Hirokazu Nagai, Kazuyuki Shimada, Norifumi Tsukamoto, 英基開発, Kensei Tobinai	2018	5
18	E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I study Cancer Science ·Elisabeth Callandret, Kiyoshi Ando, Michinori Ogura, Toshiki Uchida, Kensei Tobinai, Dai Maruyama, Masayuki Namiki, Tadashi Nakanishi	2018	25
19	Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial Cancer Science ·Dai Maruyama, Kensei Tobinai, Takaaki Chou, Masafumi Taniwaki, 丁烨 Ding Ye, Shinsuke Iida	2018	6
20	Phase I/ II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma Cancer Science ·Dai Maruyama, Hirokazu Nagai, Yoshinobu Maeda, Takahiko Nakane, Tatsu Shimoyama, Tomonori Nakazato, Rika Sakai, Takayuki Ishikawa, Koji Izutsu, Ryuzo Ueda, Kensei Tobinai	2017	24

About Dai Maruyama

Dai Maruyama is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Neurology, having authored 164 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (109 papers), Viral-associated cancers and disorders (44 papers), Chronic Lymphocytic Leukemia Research (42 papers), CNS Lymphoma Diagnosis and Treatment (23 papers), CAR-T cell therapy research (23 papers), Multiple Myeloma Research and Treatments (19 papers), T-cell and Retrovirus Studies (12 papers) and Cutaneous lymphoproliferative disorders research (12 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.0k citations), Genetics (329 citations), Oncology (816 citations), Neurology (280 citations) and Dermatology (163 citations). Dai Maruyama has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Kensei Tobinai, Yukio Kobayashi, Akiko Miyagi Maeshima, Wataru Munakata, Shinichi Makita, Suguru Fukuhara, Hirokazu Taniguchi, Takashi Watanabe, Yoshihiro Matsuno and Junko Nomoto. Their work appears in journals such as International Journal of Hematology, Blood, Japanese Journal of Clinical Oncology, Cancer Science and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact